PDF(Pubmed)
Abstract：
UNASSIGNED: Emotionally unstable personality disorder (EUPD) is debilitating psychiatric disorder, particularly common in female and forensic populations. However, appropriate pharmacological treatment to effectively manage symptoms of EUPD remains an unmet clinical need. Dopamine receptor partial agonists (DRPAs), such as aripiprazole, have a favourable tolerability profile and have demonstrated some benefits in targeting symptoms of emotional dysregulation, although, evidence regarding the effects of novel D2/D3 DRPA cariprazine in EUPD patients has been limited.
UNASSIGNED: To evaluate the efficacy and tolerability of cariprazine for EUPD in a case series of female forensic inpatients where the diagnosis is more prevalent.
UNASSIGNED: Demographic and clinical information of the patients were collected from patient electronic records during their admission in a specialized NHS forensic service. Treatment response was measured using the Positive and Negative Syndrome Scale (PANSS) at baseline, 3 and 6 months and Global Clinical Impression Scale (CGI-scores) at baseline and 6 months. Tolerability and BMI, ECG QTc interval and prolactin levels were recorded prior to initiation and at 6 months.
UNASSIGNED: Eight female patients with EUPD (mean age 29.8 years, SD 5.3) were treated with cariprazine (range 3-6mg). Total CGI-scores modestly improved from 5.6 baseline to 5.0 at 6 months. There was a reduction in mean total PANSS scores from baseline to 6 months (92.5, SD 8.1 to 72.4, SD 15.8), general psychopathology (56.1 SD 6.7 to 42.5, SD9.7), positive (21.9 SD 4.6 to 17.1, SD4.8) and negative PANSS scores (14.5 SD 6.3 to 12.8, SD4.6), corresponding to a 21%, 23%, 20% and 3% mean score reduction, respectively. Cariprazine demonstrated a favourable metabolic and hormonal side effect profile with no treatment discontinuation at 6 months follow up.
UNASSIGNED: This is the first case series to evaluate the effectiveness of cariprazine in EUPD. Its efficacy in improving PANSS and CGI-S scores was overall modest and highly variable, reflective of an inherently heterogenous and comorbid patient sample but the benefits on treatment perseverance and tolerability were considerable. Cariprazine may be of particular benefit in EUPD where psychotic symptoms are co-morbid, as an augmentation strategy to clozapine, or where previous antipsychotics have caused metabolic or hormonal side effects.
UNASSIGNED: To evaluate the efficacy and tolerability of cariprazine for EUPD in a case series of female forensic inpatients where the diagnosis is more prevalent.
UNASSIGNED: Demographic and clinical information of the patients were collected from patient electronic records during their admission in a specialized NHS forensic service. Treatment response was measured using the Positive and Negative Syndrome Scale (PANSS) at baseline, 3 and 6 months and Global Clinical Impression Scale (CGI-scores) at baseline and 6 months. Tolerability and BMI, ECG QTc interval and prolactin levels were recorded prior to initiation and at 6 months.
UNASSIGNED: Eight female patients with EUPD (mean age 29.8 years, SD 5.3) were treated with cariprazine (range 3-6mg). Total CGI-scores modestly improved from 5.6 baseline to 5.0 at 6 months. There was a reduction in mean total PANSS scores from baseline to 6 months (92.5, SD 8.1 to 72.4, SD 15.8), general psychopathology (56.1 SD 6.7 to 42.5, SD9.7), positive (21.9 SD 4.6 to 17.1, SD4.8) and negative PANSS scores (14.5 SD 6.3 to 12.8, SD4.6), corresponding to a 21%, 23%, 20% and 3% mean score reduction, respectively. Cariprazine demonstrated a favourable metabolic and hormonal side effect profile with no treatment discontinuation at 6 months follow up.
UNASSIGNED: This is the first case series to evaluate the effectiveness of cariprazine in EUPD. Its efficacy in improving PANSS and CGI-S scores was overall modest and highly variable, reflective of an inherently heterogenous and comorbid patient sample but the benefits on treatment perseverance and tolerability were considerable. Cariprazine may be of particular benefit in EUPD where psychotic symptoms are co-morbid, as an augmentation strategy to clozapine, or where previous antipsychotics have caused metabolic or hormonal side effects.
摘要：
■情绪不稳定的人格障碍（EUPD）是一种使人衰弱的精神障碍，在女性和法医人群中尤其常见。然而,有效控制EUPD症状的适当药物治疗仍未满足临床需求.多巴胺受体部分激动剂(DRPAs),比如阿立哌唑,具有良好的耐受性，并且在针对情绪失调的症状方面表现出一些益处，虽然,关于新型D2/D3DRPA卡利拉嗪在EUPD患者中的作用的证据有限.
■在诊断更为普遍的一系列女性法医住院患者中，评估卡利拉嗪对EUPD的疗效和耐受性。
■患者的人口统计学和临床信息是在他们进入专门的NHS法医服务期间从患者电子记录中收集的。在基线时使用阳性和阴性综合征量表（PANSS）测量治疗反应，3和6个月以及基线和6个月时的总体临床印象量表（CGI评分）。耐受性和BMI，在开始前和6个月时记录ECGQTc间期和催乳素水平。
■8名EUPD女性患者（平均年龄29.8岁，SD5.3）用卡利拉嗪（范围3-6mg）治疗。总CGI评分在6个月时从5.6基线适度改善至5.0。从基线到6个月，PANSS平均总分降低（92.5，SD8.1至72.4，SD15.8），一般精神病理学（56.1SD6.7至42.5，SD9.7），积极（21.9SD4.6至17.1，SD4.8）和消极的PANSS得分（14.5SD6.3至12.8，SD4.6），相当于21%，23%,20%和3%的平均得分降低，分别。Cariprazine表现出良好的代谢和激素副作用，在6个月的随访中没有停止治疗。
■这是第一个评估卡利拉嗪在EUPD中有效性的病例系列。其在改善PANSS和CGI-S评分方面的功效总体适度且高度可变，反映了固有的异质性和合并症患者样本，但对治疗毅力和耐受性的益处是相当大的。Cariprazine可能在EUPD中特别有益，在EUPD中，精神病症状是共病的，作为氯氮平的补充策略，或以前的抗精神病药引起代谢或激素副作用的地方。
■在诊断更为普遍的一系列女性法医住院患者中，评估卡利拉嗪对EUPD的疗效和耐受性。
■患者的人口统计学和临床信息是在他们进入专门的NHS法医服务期间从患者电子记录中收集的。在基线时使用阳性和阴性综合征量表（PANSS）测量治疗反应，3和6个月以及基线和6个月时的总体临床印象量表（CGI评分）。耐受性和BMI，在开始前和6个月时记录ECGQTc间期和催乳素水平。
■8名EUPD女性患者（平均年龄29.8岁，SD5.3）用卡利拉嗪（范围3-6mg）治疗。总CGI评分在6个月时从5.6基线适度改善至5.0。从基线到6个月，PANSS平均总分降低（92.5，SD8.1至72.4，SD15.8），一般精神病理学（56.1SD6.7至42.5，SD9.7），积极（21.9SD4.6至17.1，SD4.8）和消极的PANSS得分（14.5SD6.3至12.8，SD4.6），相当于21%，23%,20%和3%的平均得分降低，分别。Cariprazine表现出良好的代谢和激素副作用，在6个月的随访中没有停止治疗。
■这是第一个评估卡利拉嗪在EUPD中有效性的病例系列。其在改善PANSS和CGI-S评分方面的功效总体适度且高度可变，反映了固有的异质性和合并症患者样本，但对治疗毅力和耐受性的益处是相当大的。Cariprazine可能在EUPD中特别有益，在EUPD中，精神病症状是共病的，作为氯氮平的补充策略，或以前的抗精神病药引起代谢或激素副作用的地方。
